Hisamitsu Pharmaceutical Co., Inc. (TYO: 4530)

Market Cap	302.10B
Revenue (ttm)	150.19B
Net Income (ttm)	14.65B
Shares Out	73.34M
EPS (ttm)	194.73
PE Ratio	21.15
Forward PE	18.29
Dividend	86.00 (2.09%)
Ex-Dividend Date	Feb 27, 2025

Volume	177,300
Open	4,138.00
Previous Close	4,081.00
Day's Range	4,092.00 - 4,151.00
52-Week Range	3,600.00 - 4,593.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Jan 9, 2025

About Hisamitsu Pharmaceutical Co.

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United St...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1847
• Employees: 2,759
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4530

Financial Performance

In 2023, Hisamitsu Pharmaceutical Co.'s revenue was 141.71 billion, an increase of 10.42% compared to the previous year's 128.33 billion. Earnings were 13.97 billion, an increase of 18.97%.